As of 2023, over ** percent of diabetic patients in Germany experienced some kind of neuropathy. Pressure imbalances was the second most common risk factor experienced by diabetics. This statistic displays the percentage of diabetic patients who experienced selected risk factors in Germany, as of 2023.

Participation in the National Health Insurance "Diabetes Quality Payment Service (before September 101 (inclusive), it was the Diabetes Medical Benefit Improvement Plan)" medical institutions will take in diabetic patients and follow clinical care guidelines to provide comprehensive team professional care including examination, testing, health education, and follow-up care to reduce the occurrence of diabetic complications and comorbidities, and enhance the quality of care for patients. This quality indicator refers to the ratio of diabetic patients who are admitted to medical institutions and included in the National Health Insurance "Diabetes Quality Payment Service (before September 101 (inclusive), it was the Diabetes Medical Benefit Improvement Plan)" during the statistical period. A higher ratio indicates better care quality. This indicator is compiled by the National Health Insurance Administration based on statistics reported by each medical institution.

This statistic depicts the rate of hospital readmissions in the United States for patients diagnosed with type 2 diabetes between 2020-2022, by therapy type. During these years, around ** percent of those diagnosed with diabetes were readmitted within ***** days for ***** non-insulin products.

Participating healthcare institutions in the "Diabetes Quality Payment Service (before September 101 (including) was the Diabetes Medical Benefit Improvement Plan)" will accept diabetes patients and provide comprehensive team-based professional care including examination, testing, health education, and follow-up according to clinical care guidelines to reduce the occurrence of diabetes complications and comorbidities, which can improve the quality of care for patients. This quality indicator refers to the ratio of diabetes patients who have been accepted by healthcare institutions and joined the National Health Insurance "Diabetes Quality Payment Service (before September 101 (including) was the Diabetes Medical Benefit Improvement Plan)" during the statistical period. A higher ratio indicates better quality of care. This indicator is compiled by the Central Health Insurance Administration based on the reported data from each healthcare institution.

United States US: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 10.790 % in 2017. United States US: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 10.790 % from Dec 2017 (Median) to 2017, with 1 observations. United States US: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes.; ; International Diabetes Federation, Diabetes Atlas.; Weighted average;

In 2024, around 16 percent of adults between the ages of 20 and 79 had diabetes in Turkey. Other selected countries with a high prevalence of diabetes that year included Mexico, the United States, and Portugal. Diabetes is a metabolic disease that causes high blood sugar levels. Diabetes worldwide In 2024, an estimated 11 percent of the global adult population had diabetes. In concrete numbers, there were about 589 million diabetic adults (20-79 years) worldwide in 2024, and this total is predicted to grow to approximately 852.5 million by the year 2050. Spending per patient The country that spent the most on patients with diabetes in 2024 was Switzerland. At that time, providing for a diabetic patient in Switzerland cost an average of over 12 thousand U.S. dollars. The United States stood in second place, spending about 10,500 U.S. dollars per patient. In the same year, the ten countries by lowest average spending per person with diabetes were all African and Asian countries. Bangladesh had the lowest annual diabetes-related health expenditures per person, with just 74 U.S. dollars.

Diabetes prevalence in Massachusetts has been steadily increasing.

Number and percentage of persons having been diagnosed with diabetes, by age group and sex.

The National Diabetes Audit (NDA) provides a comprehensive view of diabetes care in England and Wales. It measures the effectiveness of diabetes healthcare against National Institute for Health and Care Excellence (NICE) Clinical Guidelines and NICE Quality Standards. This NICE guidance is based on evidence that regular systematic review of people with diabetes and achievement of glucose, blood pressure and cardiovascular risk standards maintains health and reduces long term complications.

BackgroundThe neutrophil-percentage-to-albumin ratio (NPAR), as a low-cost and easily accessible inflammatory biomarker, has garnered considerable attention in various disease studies in recent years. Specifically, existing research has suggested a significant correlation between NPAR and diabetic retinopathy, indicating its potential relevance to diabetic complications. However, despite diabetic kidney disease (DKD) being a complication that severely affects the quality of life of diabetic patients, the association between the prevalence of DKD and NPAR remains to be elucidated. Therefore, this study aims to explore the potential link between NPAR and DKD in patients with type 2 diabetes mellitus.MethodsWe extracted complete data on neutrophil percentage, plasma albumin, serum creatinine, and urine albumin-to-creatinine ratio from the National Health and Nutrition Examination Survey database spanning from 2009 to 2018. Multivariable logistic regression models were employed to examine the relationship between NPAR levels and DKD, and conducted sensitivity tests, subsequently employing Generalized Additive Models combined with smooth curve fitting methods to explore the relationships among variables. Then, subgroup analyses were conducted on the association between NPAR and DKD to investigate changes in the relationship across different subgroups. Finally, Receiver operating characteristic curves were used to assess the predictive performance of the independent variable, NPAR, for the dependent variable, DKD.ResultsA total of 2,263 participants were enrolled in this cross-sectional study. After adjusting for confounding factors, the odds ratio for DKD was 1.44 (95% CI: 1.08-1.90) for the second quartile group, 1.75 (95% CI: 1.33-2.31) for the third quartile group, and 2.95 (95% CI: 2.22-3.93) for the fourth quartile group. Among patients with type 2 diabetes mellitus, a positive correlation was observed between NPAR and DKD. Results from subgroup analyses showed no significant differences among different populations. Receiver operating characteristic (ROC) analysis indicated that NPAR had good predictive performance for DKD.ConclusionThe prevalence of DKD indicated a positive association with NPAR among individuals with T2DM. Additional large-scale prospective investigations may be helpful in corroborating these findings.

As of 2023, about ** percent of diabetic patients in Germany knew about diabetic foot syndrome (DFS) and its related risks, while only ** percent had no knowledge of it. Conversely, over ** percent of diabetic patients had no familiarity with foot ulcers. This statistic displays the distribution of diabetic patients who knew what diabetic foot syndrome (DFS) and foot ulcers were and their associated risks in Germany, as of 2023.

Population-based county-level estimates for diagnosed (DDP), undiagnosed (UDP), and total diabetes prevalence (TDP) were acquired from the Institute for Health Metrics and Evaluation (IHME) for the years 2004-2012 (Evaluation 2017). Prevalence estimates were calculated using a two-stage approach. The first stage used National Health and Nutrition Examination Survey (NHANES) data to predict high fasting plasma glucose (FPG) levels (≥126 mg/dL) and/or hemoglobin A1C (HbA1C) levels (≥6.5% [48 mmol/mol]) based on self-reported demographic and behavioral characteristics (Dwyer-Lindgren, Mackenbach et al. 2016). This model was then applied to Behavioral Risk Factor Surveillance System (BRFSS) data to impute high FPG and/or A1C status for each BRFSS respondent (Dwyer-Lindgren, Mackenbach et al. 2016). The second stage used the imputed BRFSS data to fit a series of small area models, which were used to predict the county-level prevalence of each of the diabetes-related outcomes (Dwyer-Lindgren, Mackenbach et al. 2016). Diagnosed diabetes was defined as the proportion of adults (age 20+ years) who reported a previous diabetes diagnosis, represented as an age-standardized prevalence percentage. Undiagnosed diabetes was defined as proportion of adults (age 20+ years) who have a high FPG or HbA1C but did not report a previous diagnosis of diabetes. Total diabetes was defined as the proportion of adults (age 20+ years) who reported a previous diabetes diagnosis and/or had a high FPG/HbA1C. The age-standardized diabetes prevalence (%) was used as the outcome. The EQI was constructed for 2000-2005 for all US counties and is composed of five domains (air, water, built, land, and sociodemographic), each composed of variables to represent the environmental quality of that domain. Domain-specific EQIs were developed using principal components analysis (PCA) to reduce these variables within each domain while the overall EQI was constructed from a second PCA from these individual domains (L. C. Messer et al., 2014). To account for differences in environment across rural and urban counties, the overall and domain-specific EQIs were stratified by rural urban continuum codes (RUCCs) (U.S. Department of Agriculture, 2015). This dataset is not publicly accessible because: EPA cannot release personally identifiable information regarding living individuals, according to the Privacy Act and the Freedom of Information Act (FOIA). This dataset contains information about human research subjects. Because there is potential to identify individual participants and disclose personal information, either alone or in combination with other datasets, individual level data are not appropriate to post for public access. Restricted access may be granted to authorized persons by contacting the party listed. It can be accessed through the following means: Human health data are not available publicly. EQI data are available at: https://edg.epa.gov/data/Public/ORD/NHEERL/EQI. Format: Data are stored as csv files. This dataset is associated with the following publication: Jagai, J., A. Krajewski, S. Shaikh, D. Lobdell, and R. Sargis. Association between environmental quality and diabetes in the U.S.A.. Journal of Diabetes Investigation. John Wiley & Sons, Inc., Hoboken, NJ, USA, 11(2): 315-324, (2020).

The percentage of patients aged 17 or over with diabetes mellitus, as recorded on practice disease registers.

Note on ward level data This data is GP practice level data taken from Fingertips and converted to wards using our Fingertips GP to Ward Lookup Matrix for Birmingham and Solihull dataset. This dataset uses the GP census to allocate an approximate percentage of their patients to each ward based on the citizens home address.

Rationale Diabetes mellitus is one of the common endocrine diseases affecting all age groups, with over three million people in the UK having the condition. Effective control and monitoring can reduce mortality and morbidity. Much of the management and monitoring of diabetic patients, particularly patients with Type 2 diabetes, is undertaken by the GP and members of the primary care team.

Definition of numerator Patients aged 17+ years with diabetes mellitus.

Definition of denominator Total number of patients aged 17+ years registered with the practice.

Caveats None

The National Diabetes Audit (NDA) provides a comprehensive view of diabetes care in England and Wales. It measures the effectiveness of diabetes healthcare against NICE Clinical Guidelines and NICE Quality Standards. This is the Type 1 Diabetes report. It details the findings and recommendations relating to diabetes care process completion, treatment target achievement and structured education for people with type 1 diabetes. The 2019-20 audit covers the period 01 January 2019 to 31 March 2020. This is the first NDA report dedicated to people with type 1 diabetes. A new diagnosis validation process, which considers medication as well as recorded diagnosis, has been introduced to try to ensure that only people with true type 1 diabetes are included (see appendix). Results are to be taken in the context of low data submission from specialist services, possibly hampered due to COVID-19.

The national health insurance is recommended to use glycated hemoglobin (HbA1c) or glycated albumin, fasting lipid profile, fundus examination or fundus color photography, and urine protein (microalbumin) as four indicators for medical institutions to assess the quality of care for diabetic patients before seeking medical treatment.

Source of data: Medical service point declaration data from the insurance medical service organization. Numerator: People who had "fasting blood lipid test" performed in the denominator ID in the same year. Denominator: Patients with primary or secondary diagnosis of diabetes and use of diabetes medication in outpatient department. Calculation formula: (Numerator / Denominator) x100%

Diabetes Treatment Market Outlook

The global diabetes treatment market size was valued at approximately $50 billion in 2023 and is projected to reach around $90 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.5%. This significant growth is primarily driven by the increasing prevalence of diabetes worldwide, advancements in medical technology, and a rising awareness of diabetes management and treatment options.

One of the primary growth factors for the diabetes treatment market is the increasing prevalence of diabetes globally. According to the International Diabetes Federation, the number of people with diabetes is expected to rise from 463 million in 2019 to 700 million by 2045. This alarming increase highlights the urgent need for effective diabetes management and treatment solutions, driving demand in the market. Additionally, lifestyle changes such as urbanization and diet shifts contribute to the rising diabetes rates, further fueling market growth.

Technological advancements in diabetes treatment are another significant growth catalyst. Innovations in insulin delivery systems, continuous glucose monitoring (CGM) devices, and artificial pancreas systems are transforming diabetes care. Improved accuracy, convenience, and patient compliance offered by these technologies enhance diabetes management, thereby boosting market demand. The integration of digital health technologies, such as mobile health apps and telemedicine, also plays a crucial role in supporting diabetes management and monitoring, propelling market growth.

Government initiatives and supportive policies are also driving the growth of the diabetes treatment market. Many governments across the globe are implementing national diabetes programs to improve diabetes care and management. These programs often include funding for research, subsidies for diabetes medications and devices, and public awareness campaigns. Furthermore, collaborations between public and private sectors are fostering innovation and accessibility in diabetes treatment, which is expected to sustain market growth over the forecast period.

From a regional perspective, North America holds a significant share of the diabetes treatment market due to the high prevalence of diabetes, well-established healthcare infrastructure, and strong presence of key market players. Europe follows closely, driven by a growing diabetic population and favorable reimbursement policies. The Asia Pacific region is anticipated to witness the fastest growth, attributed to increasing urbanization, rising healthcare expenditure, and a large undiagnosed diabetic population. Meanwhile, Latin America and the Middle East & Africa regions are expected to experience steady growth owing to improving healthcare access and growing awareness of diabetes management.

Product Type Analysis

In the diabetes treatment market, the product type segment is categorized into Insulin, Oral Hypoglycemic Agents, Non-Insulin Injectable Drugs, and Others. Insulin remains a cornerstone in diabetes management, particularly for individuals with Type 1 diabetes and advanced Type 2 diabetes. The development of various insulin formulations, such as rapid-acting, long-acting, and premixed insulins, caters to the diverse needs of diabetic patients. Additionally, innovations like insulin pens and pumps enhance the convenience and accuracy of insulin administration, supporting the growth of this segment.

Oral Hypoglycemic Agents (OHAs) represent another critical segment in diabetes treatment, particularly for Type 2 diabetes management. OHAs include medications such as metformin, sulfonylureas, DPP-4 inhibitors, and SGLT-2 inhibitors, which help to lower blood glucose levels through different mechanisms. The increasing prevalence of Type 2 diabetes, along with a growing focus on combination therapies to improve glycemic control, is driving the demand for OHAs. Additionally, the development of new classes of oral medications with improved efficacy and safety profiles is expected to further boost this segment.

Non-Insulin Injectable Drugs, including GLP-1 receptor agonists and amylin analogs, offer alternative treatment options for diabetes management. These injectable drugs help to control blood sugar levels and provide additional benefits such as weight loss and cardiovascular protection. The growing preference for non-insulin injectables among patients and healthcare providers is contributing to the expansion of this segment. Moreover, ongoing research and development efforts aimed at enhancing the delivery and efficacy of these

It was estimated that as of 2023, around **** million people in the United States had been diagnosed with diabetes. The number of people diagnosed with diabetes in the U.S. has increased in recent years and the disease is now a major health issue. Diabetes is now the seventh leading cause of death in the United States, accounting for ******percent of all deaths. What is prediabetes? A person is considered to have prediabetes if their blood sugar levels are higher than normal but not high enough to be diagnosed with type 2 diabetes. As of 2021, it was estimated that around ** million men and ** million women in the United States had prediabetes. However, according to the CDC, around ** percent of these people do not know they have this condition. Not only does prediabetes increase the risk of developing type 2 diabetes, but also increases the risk of heart disease and stroke. The states with the highest share of adults who had ever been told they have prediabetes are California, Hawaii, and New Mexico. The prevalence of diabetes in the United States As of 2023, around *** percent of adults in the United States had been diagnosed with diabetes, an increase from ****percent in the year 2000. Diabetes is much more common among older adults, with around ** percent of those aged 60 years and older diagnosed with diabetes, compared to just ****percent of those aged 20 to 39 years. The states with the highest prevalence of diabetes among adults are West Virginia, Mississippi, and Louisiana, while Utah and Colorado report the lowest rates. In West Virginia, around ** percent of adults have been diagnosed with diabetes.

Diabetes Management Platform Market Outlook

The global diabetes management platform market is projected to grow significantly, with a market size valued at approximately $18 billion in 2023 and expected to surge to nearly $35 billion by 2032, reflecting a robust compound annual growth rate (CAGR) of 7.5%. This growth is primarily driven by the increasing prevalence of diabetes globally, advancements in healthcare technology, and the growing awareness and need for effective diabetes management solutions. The diabetes management platform market is witnessing profound changes due to technological innovations, increased healthcare expenditure, and the integration of artificial intelligence and machine learning in healthcare platforms, which are enhancing patient outcomes and streamlining diabetes management processes.

A major growth factor in the diabetes management platform market is the increasing prevalence of diabetes worldwide. With lifestyle changes and rising obesity rates, diabetes has become a global health challenge, necessitating advanced management solutions. The International Diabetes Federation estimates that the number of people with diabetes is expected to rise, fueling the demand for effective management platforms. These platforms offer real-time monitoring and data analytics, which are critical in managing the disease effectively. Moreover, increasing health awareness and the push for preventive healthcare have prompted patients and healthcare providers to adopt comprehensive management systems that offer holistic care solutions, further driving market growth.

Technological advancements are another pivotal growth driver for the diabetes management platform market. The integration of digital health technologies, such as telemedicine, artificial intelligence, and mobile health applications, has revolutionized diabetes management, making it more efficient and patient-centric. Companies are investing heavily in research and development to enhance the capabilities of diabetes management platforms, offering features like predictive analytics, personalized treatment plans, and real-time monitoring. These innovations are not only improving patient adherence and outcomes but also enabling healthcare providers to offer more precise and personalized care, thereby accelerating market expansion.

The increasing focus on personalized medicine is also fueling the growth of the diabetes management platform market. Patients are increasingly seeking tailored treatments that cater to their specific needs, propelling the demand for platforms that offer customized solutions. Personalized diabetes management platforms use data analytics and machine learning to analyze patient data and provide individualized treatment plans, enhancing patient engagement and adherence. This shift towards personalized care is not only improving clinical outcomes but also reducing the overall healthcare costs, making diabetes management platforms an attractive solution for both patients and healthcare providers.

Diabetes Management Devices play a crucial role in the evolving landscape of diabetes care. These devices, including glucose meters, insulin pumps, and continuous glucose monitoring systems, are integral to the effective management of diabetes. With technological advancements, these devices have become more accurate, user-friendly, and connected, allowing for seamless integration with digital health platforms. This integration not only enhances the monitoring capabilities but also provides patients and healthcare providers with real-time data, enabling timely interventions and personalized treatment plans. As the demand for efficient and comprehensive diabetes management solutions grows, the development and adoption of advanced diabetes management devices are expected to accelerate, contributing significantly to the overall market expansion.

Regionally, the diabetes management platform market exhibits diverse growth patterns. North America holds a substantial share of the market, driven by a high prevalence of diabetes, advanced healthcare infrastructure, and significant investments in digital health technologies. Europe follows closely, with a focus on innovative healthcare solutions and favorable government initiatives supporting diabetes management. In the Asia Pacific region, the market is witnessing rapid growth due to the increasing diabetic population, rising healthcare expenditure, and growing awareness about diabetes management. Emerging economies in Latin America and the Middle East & Africa are also showing potential for gr

This is an overview of the treatment and demographics of 227,435 adults with type 1 diabetes. From 2019 to 2022 glucose control in people with type 1 diabetes in England and Wales improved while blood pressure control deteriorated. Use of diabetes technology (wearable glucose monitoring devices in England and insulin pumps in England and Wales) was associated with lower glucose levels. Diabetes technology was used less by those in the most deprived groups and in ethnic minorities. 30% of people with type 1 diabetes did not attend specialist care in 2021-22 and were less likely to receive annual checks or achieve treatment targets as recommended by the National Institute for Health and Care Excellence (NICE). There are 3 recommendations for commissioners of care.